PL4244396T3 - Sposoby identyfikacji pacjentów z hiv wrażliwych na terapię przeciwciałami skierowanymi na miejsce wiązania cd4 gp120 - Google Patents

Sposoby identyfikacji pacjentów z hiv wrażliwych na terapię przeciwciałami skierowanymi na miejsce wiązania cd4 gp120

Info

Publication number
PL4244396T3
PL4244396T3 PL21816279.0T PL21816279T PL4244396T3 PL 4244396 T3 PL4244396 T3 PL 4244396T3 PL 21816279 T PL21816279 T PL 21816279T PL 4244396 T3 PL4244396 T3 PL 4244396T3
Authority
PL
Poland
Prior art keywords
therapy
methods
binding site
hiv patients
directed antibodies
Prior art date
Application number
PL21816279.0T
Other languages
English (en)
Inventor
Stephen R. Martin
Brian Moldt
Aiyappa Parvangada
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of PL4244396T3 publication Critical patent/PL4244396T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C07K16/1145—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
PL21816279.0T 2020-11-11 2021-11-09 Sposoby identyfikacji pacjentów z hiv wrażliwych na terapię przeciwciałami skierowanymi na miejsce wiązania cd4 gp120 PL4244396T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063112512P 2020-11-11 2020-11-11
PCT/US2021/058638 WO2022103758A1 (en) 2020-11-11 2021-11-09 METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES

Publications (1)

Publication Number Publication Date
PL4244396T3 true PL4244396T3 (pl) 2025-12-22

Family

ID=78819682

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21816279.0T PL4244396T3 (pl) 2020-11-11 2021-11-09 Sposoby identyfikacji pacjentów z hiv wrażliwych na terapię przeciwciałami skierowanymi na miejsce wiązania cd4 gp120

Country Status (13)

Country Link
US (1) US20220144923A1 (pl)
EP (2) EP4660325A2 (pl)
JP (2) JP7659628B2 (pl)
KR (1) KR20230107288A (pl)
CN (1) CN116437958A (pl)
AU (2) AU2021377614B2 (pl)
CA (1) CA3195799A1 (pl)
ES (1) ES3045091T3 (pl)
PL (1) PL4244396T3 (pl)
PT (1) PT4244396T (pl)
SI (1) SI4244396T1 (pl)
TW (2) TWI814130B (pl)
WO (1) WO2022103758A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240083984A1 (en) 2022-08-26 2024-03-14 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
SI1301519T1 (sl) 2000-07-21 2015-07-31 Gilead Sciences, Inc. Predzdravila fosfonatnih nukleotidnih analogov in postopki za izbiro in izdelavo le-teh
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
SG182849A1 (en) 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
DK1778251T3 (da) 2004-07-27 2011-07-18 Gilead Sciences Inc Nukleosidphosphatkonjugater som anti-HIV-midler
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
MX2009000234A (es) 2006-07-07 2009-01-23 Gilead Sciences Inc Moduladores de las propiedades farmacocineticas de productos terapeuticos.
KR101561710B1 (ko) 2007-06-29 2015-10-19 길리애드 사이언시즈, 인코포레이티드 퓨린 유도체 및 그것의 톨 유사 수용체 7의 조절 인자로서 용도
KR20100097156A (ko) 2007-11-16 2010-09-02 베링거 인겔하임 인터내셔날 게엠베하 사람 면역결핍 바이러스 복제의 억제제
AU2009240642B2 (en) 2008-04-23 2013-08-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
AU2009276403B2 (en) 2008-08-01 2016-03-10 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
AU2010284240B2 (en) 2009-08-18 2016-11-10 Array Biopharma, Inc. Substituted benzoazepines as Toll-like receptor modulators
US8524702B2 (en) 2009-08-18 2013-09-03 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
CN102666541B (zh) 2009-10-22 2015-11-25 吉里德科学公司 用于治疗特别是病毒感染的嘌呤或脱氮嘌呤的衍生物
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
CN103140474A (zh) 2010-07-02 2013-06-05 吉里德科学公司 治疗aids的萘-2-基乙酸衍生物
ES2669793T3 (es) 2010-07-02 2018-05-29 Gilead Sciences, Inc. Derivados de 2-quinolinil-ácido acético como compuestos antivirales del VIH
US20120027752A1 (en) 2010-07-22 2012-02-02 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections
PL3556396T3 (pl) 2010-08-31 2022-09-12 Theraclone Sciences, Inc. Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv)
RU2587061C2 (ru) 2010-10-01 2016-06-10 Вентиркс Фармасьютикалз, Инк. Способы лечения аллергических заболеваний
NZ608673A (en) 2010-10-01 2015-04-24 Univ Pennsylvania Therapeutic use of a tlr agonist and combination therapy
EP3207930A1 (en) 2011-01-12 2017-08-23 VentiRx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
ES2620606T3 (es) 2011-01-12 2017-06-29 Ventirx Pharmaceuticals, Inc. Benzoazepinas sustituidas como moduladores de receptores tipo Toll
SMT202000196T1 (it) 2011-04-08 2020-05-08 Janssen Sciences Ireland Unlimited Co Derivati di pirimidina per il trattamento di infezioni virali
ES2615734T3 (es) 2011-04-21 2017-06-08 Gilead Sciences, Inc. Compuestos de benzotiazol y su uso farmacéutico
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
IL313030A (en) 2011-05-17 2024-07-01 Univ Rockefeller Human immunodeficiency virus neutralizing antibodies and methods of use thereof
PH12013502382B1 (en) 2011-05-18 2021-09-22 Janssen Sciences Ireland Uc Quinazoline derivatives for the treatment of viral infections and further diseases
EP2729448B1 (en) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
EP2736532B1 (en) 2011-07-25 2018-05-16 California Institute of Technology Compositions and methods for improving potency and breadth or hiv antibodies
BR112014003420B1 (pt) 2011-08-16 2021-07-20 Gilead Sciences, Inc Hemifumarato de tenofovir alafenamida. composição, seus métodos de preparação e uso
AU2012319172B2 (en) 2011-10-07 2014-06-12 Gilead Sciences, Inc. Methods for preparing anti-viral nucleotide analogs
CA2858716C (en) 2011-12-08 2021-10-12 Peter D. Kwong Neutralizing antibodies to hiv-1 and their use
EP2794613B1 (en) 2011-12-20 2017-03-29 Boehringer Ingelheim International GmbH Condensed triclyclic compounds as inhibitors of hiv replication
DK2794565T3 (da) 2011-12-21 2017-11-13 Novira Therapeutics Inc Antivirale midler mod hepatitis b
JP6283320B2 (ja) 2012-02-08 2018-02-21 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染の治療のためのピペリジノ−ピリミジン誘導体
EA201490647A1 (ru) 2012-04-20 2014-12-30 Джилид Сайэнс, Инк. Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
IN2015MN00478A (pl) 2012-08-10 2015-09-04 Janssen Sciences Ireland Uc
PL2906563T3 (pl) 2012-10-10 2018-10-31 Janssen Sciences Ireland Uc Pochodne pirolo[3,2-d]pirymidyny do leczenia infekcji wirusowych i innych chorób
JP6461804B2 (ja) 2012-10-18 2019-01-30 ザ ロックフェラー ユニバーシティー 広域中和抗ｈｉｖ抗体
CN105051018B (zh) 2012-11-16 2019-09-20 爱尔兰詹森科学公司 用于治疗病毒性感染的杂环的经取代的2-氨基-喹唑啉衍生物
AU2013361401C1 (en) 2012-12-21 2018-08-09 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
MX2015008467A (es) 2012-12-27 2015-09-23 Japan Tobacco Inc Derivado sustituido de espiropirido[1,2-a]pirazina y uso medico del mismo como inhibidor de la integrasa del virus de inmunodeficiencia humana.
EP2958900B1 (en) 2013-02-21 2019-04-10 Janssen Sciences Ireland Unlimited Company 2-aminopyrimidine derivatives for the treatment of viral infections
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
NO2717902T3 (pl) 2014-06-20 2018-06-23
CA2972017C (en) 2014-12-24 2019-06-11 Gilead Sciences, Inc. Isoquinoline compounds for the treatment of hiv
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
EA032430B1 (ru) 2014-12-24 2019-05-31 Джилид Сайэнс, Инк. Конденсированные пиримидины для лечения вич
US10344077B2 (en) 2015-03-19 2019-07-09 Duke University HIV-1 neutralizing antibodies and uses thereof (V3 antibodies)
US10259882B2 (en) 2015-05-07 2019-04-16 Agenus Inc. Anti-OX40 antibodies
AU2016322763A1 (en) 2015-09-15 2018-04-19 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of HIV
MA43389A (fr) 2015-12-02 2021-05-12 Agenus Inc Anticorps anti-ox40 et leurs procédés d'utilisation
WO2017096276A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
US20200123265A1 (en) 2015-12-02 2020-04-23 Agenus Inc. Anti-gitr antibodies and methods of use thereof
CN108883173B (zh) 2015-12-02 2022-09-06 阿吉纳斯公司 抗体和其使用方法
CA3006963A1 (en) 2015-12-03 2017-06-08 Ludwig Institute For Cancer Research Ltd. Anti-ox40 antibodies and methods of use thereof
SI3390441T1 (sl) 2015-12-15 2021-11-30 Gilead Sciences, Inc. Protitelesa, ki nevtralizirajo virus humane imunske pomanjkljivosti
MX369307B (es) 2016-08-19 2019-11-05 Gilead Sciences Inc Compuestos terapeuticos utiles para tratamiento profilactico o terapeutico de infeccion por virus de inmunodeficiencia humana.
WO2018075564A1 (en) 2016-10-17 2018-04-26 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
AU2017359467A1 (en) 2016-11-09 2019-05-02 Agenus Inc. Anti-OX40 antibodies, anti-GITR antibodies, and methods of use thereof
CN116948018A (zh) 2016-12-27 2023-10-27 洛克菲勒大学 广谱中和抗hiv-1抗体及其使用方法
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
CN110831965B (zh) 2017-06-21 2023-03-07 吉利德科学公司 靶向hiv gp120和cd3的多特异性抗体
CN111032688A (zh) * 2017-08-11 2020-04-17 研究发展基金会 用于延长的血清半衰期的工程化抗体fc变体
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
US11274102B2 (en) 2017-10-30 2022-03-15 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
US11845788B2 (en) 2018-05-22 2023-12-19 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (HIV)
ES3034066T3 (en) * 2018-07-03 2025-08-12 Gilead Sciences Inc Antibodies that target hiv gp120 and methods of use
EP3830108A4 (en) 2018-07-27 2022-08-10 International AIDS Vaccine Initiative GENETIC ANTIBODIES AGAINST HIV-ENV
TWI829205B (zh) 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物
WO2020056145A1 (en) 2018-09-14 2020-03-19 The Rockefeller University Anti-hiv antibody 10-1074 variants

Also Published As

Publication number Publication date
EP4244396A1 (en) 2023-09-20
ES3045091T3 (en) 2025-11-27
JP7659628B2 (ja) 2025-04-09
WO2022103758A1 (en) 2022-05-19
AU2025213651A1 (en) 2025-08-28
EP4244396B1 (en) 2025-08-13
PT4244396T (pt) 2025-10-20
AU2021377614B2 (en) 2025-05-15
EP4660325A2 (en) 2025-12-10
TW202225186A (zh) 2022-07-01
JP2024107366A (ja) 2024-08-08
AU2021377614A9 (en) 2024-07-04
US20220144923A1 (en) 2022-05-12
AU2021377614A1 (en) 2023-06-22
KR20230107288A (ko) 2023-07-14
SI4244396T1 (sl) 2025-10-30
TW202402788A (zh) 2024-01-16
JP2023549188A (ja) 2023-11-22
CA3195799A1 (en) 2022-05-19
CN116437958A (zh) 2023-07-14
TWI814130B (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
BR112018076767A2 (pt) anticorpos de ligação a cd3
Watkins et al. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission
SA522431672B1 (ar) Cd3 أجسام مضادة للارتباط بـ
PH12021500001A1 (en) Antibodies that target hiv gp120 and methods of use
CA2864995C (en) Ingenol derivatives in the reactivation of latent hiv virus
EA201890782A1 (ru) Способ перенацеливания t-клеток для лечения инфекции hiv
PT4244396T (pt) Métodos de identificação de doentes com hiv sensíveis à terapia com anticorpos dirigidos ao sítio de ligação cd4 da gp120
WO2011038290A3 (en) Neutralizing antibodies to hiv-1 and their use
NZ748314A (en) Anti-cmet antibody drug conjugates and methods for their use
PH12018501977A1 (en) Cell injury inducing therapeutic drug for use in cancer theraphy
PH12015501814B1 (en) Novel insulin analog and use thereof
NZ743815A (en) Tetravalent anti-psgl-1 antibodies and uses thereof
PH12019502302A1 (en) Anti-pd-l1 antibody and use thereof
NZ606992A (en) Drug and method for the prophylaxis of hiv infection and for the prophylaxis and treatment of diseases caused by or associated with hiv, including aids
EP4513188A3 (en) Methods of identifying hiv patients sensitive to therapy with gp120 v3 glycan-directed antibodies
HK40100080A (en) Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies
WO2017177217A3 (en) Chimeric receptors and uses thereof in immune therapy
EP4267609A4 (en) ANTIBODIES AGAINST HUMAN AND SIMPLE CD3 AND USES THEREOF
Mapanawang et al. Pangi leaf (Pangium edule Reinw) herbal medicine: a marvelous candidate for the prominent hiv herbal medicine
HK40127014A (en) Methods of identifying hiv patients sensitive to therapy with gp120 v3 glycan-directed antibodies
MX2024009093A (es) Aparato de flejado.
CN203861667U (zh) 一种带止血带的输液器
MD975Y (ro) Metodă de determinare a markerilor hepatitei virale B în sângele donatorului
WO2022073966A3 (de) Verfahren und vorrichtung zur herstellung von universalplasma
Haynes et al. HIV broadly neutralizing antibodies for treatment, prevention and vaccine design